Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 1997

View Archived Issues

Coulter: Q3 1997 highlights

Faulding: Q1 1998 highlights

CoCensys: Q3 1997 highlights

SIBIA Neurosciences: Q3 1997 highlights

Pharmacopeia: Q3 and nine-month 1997 highlights

Protein C and sepsis

ILEX Oncology: Q3 1997 highlights

Boehringer Ingelheim to acquire Ben Venue; new company formed

Cell Genesys reports delivery of erythropoietin gene therapy

New azole antifungals from Zambon/Isagro

Profile of Green Cross's rHSA

Gastric prokinetic agents under development at Janssen

Three new launches anticipated for Pfizer in 1998

Akzo Nobel prepares two series of thrombin inhibitors

Korean researchers describe new ginseng saponins with antitumor activity

Roussel Uclaf reports new erythromycin antibiotics

Peripherally acting opioid analgesics described by Astra

U.S. approval for Raxar

AntiVirals to acquire ImmunoTherapy and its late-stage cancer vaccine

PEG-hirudin compared to established antithrombotic agents

Nyotran compared to other antifungals in vitro

SPA-S-843 compared in experimental infection models to current antifungals

Merck to develop Vical technology for therapeutic vaccines

Preclinical activity and pharmacokinetic data presented for UR-9825

Saruplase efficacy demonstrated in large patient study

Myriad creates CNS database for potential drug discovery

Gensia Sicor terminates collaboration with Atrix

Apomorphine designated orphan drug

ReoPro cleared in U.S. for expanded labeling

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...